Report ID: 10352557 |
Published Date: 28 Apr 2025 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
Executive Summary of the Cardiac Rhythm Management Devices Market
1. Global Demand by Region
The CRM devices market expanded from $26.0 billion in 2024 to $43.9 billion by 2037 with a 6.7% annual growth rate. The population aging, combined with increasing cardiovascular disease rates and new developments in implantable technology, drives market growth.
- North America (Largest Market): The Market was valued at USD 18.3 billion in 2024 and a CAGR of 5.0% during the forecast period. The United States commands 48% of worldwide CRM revenue because of widespread use of implantable cardioverter-defibrillators (ICDs) and pacemakers. The growth of the sector is driven by Medicare, which covers approximately 80% of procedures.
- Europe (Stable Growth, High Regulation): The market was valued at USD 13.9 billion in 2024 and is poised to expand at a CAGR of 3.9% during the anticipated timeline. The countries Germany and France account for 35% of regional healthcare spending as their universal healthcare systems support an older population expected to reach 27% by 2037. Year-over-year increases in remote cardiac monitoring adoption stand at 12%.
- Asia-Pacific (Fastest-Growing Region): The market was valued at USD 10.8 billion in 2024 and is projected to expand at a CAGR of 4.6% during the anticipated timeline. The Asia-Pacific market is expanding because of increasing cases of cardiovascular disease (330 million patients in China by 2037) and better access to healthcare services. Additionally, Japan is expected to achieve 40% adoption of leadless pacemakers by 2037 because of its super-aged population.
- Latin America & Middle East (Emerging Opportunities): The market is poised to expand to $4.5 billion by 2037 at a CAGR of 4.1%. Since private healthcare investments have increased by 9% YoY in Brazil's CRM market. Additionally, medical tourism combined with government-sponsored projects such as Saudi Vision 2037, enhances market demand.
2. Rapidly Growing Market Segments
Market Segmentation: The cardiac rhythm management devices market research report provides comprehensive industry analysis with revenue estimates and forecasts (USD Billion) from 2025 to 2037 across the following segments:
|
Segment |
CAGR (2025–2037) |
Market Share (2037) |
|
Implantable Cardioverter Defibrillators (ICD) |
5.4% |
$12.7 billion |
|
Remote Cardiac Monitoring |
5.2% |
$7.4 billion |
3. Regional Outlook & Payer Pricing Analysis
|
Segment |
CAGR (2025–2037) |
Market Share (2037) |
Revenue Share (2037) |
Key Markets |
|
Implantable Cardioverter Defibrillators (ICD) |
5.4% |
$12.7 billion |
45% |
U.S., Germany, Japan |
|
Leadless Pacemakers |
4.9% |
$5.5 billion |
19.5% |
Japan (40% adoption target by 2037) |
|
Remote Cardiac Monitoring |
5.2% |
$7.4 billion |
26.5% |
U.S. (FDA-cleared devices), Germany (60% adoption) |
Major Drivers of the Cardiac Rhythm Management Devices Market
- Healthcare Quality Improvement: Research from AHRQ shows that early-stage healthcare interventions play a critical role in diminishing hospitalizations and healthcare expenses. The introduction of advanced cardiac rhythm management (CRM) devices leads to better patient results and shorter hospitalizations. Additionally, CRM device efficiency has improved through quality improvement initiatives, including remote monitoring technology adoption, resulting in better patient adherence and fewer complications.
- Government and Personal Spending: The demand for CRM devices in the USA increased as Medicare expenditures on these technologies reached substantial amounts. Patients continue to face challenging out-of-pocket expenses for medical care in areas with inadequate insurance availability. Additionally, government subsidies and reimbursement policies in nations such as Germany and Japan have successfully enhanced access to these services.
- Patient Pool and Disease Prevalence: Patient numbers for cardiovascular diseases continue to increase around the world, with North America and Europe as the regions with the highest numbers. Additionally, the United States has more than 14 million people living with atrial fibrillation. The prevalence of heart rhythm disorders in Germany has risen by approximately 15% since 2018, underscoring the increasing necessity for CRM solutions.
- Technological Advancements: The market expansion is driven by the development of leadless pacemakers and wearable defibrillators alongside AI-driven diagnostic tools. Furthermore, medical innovations lead to better patient care while simultaneously decreasing healthcare system strain.
EMC Filtration Market: Key Insights
| Base Year |
2024 |
| Forecast Period |
2025-2037 |
| CAGR (2025-2037) |
6.4% |
| Base Year Market Size (2024) |
USD 6.7 billion |
| Forecast Year Market Size (2037) |
USD 11.09 billion |
| Segments Covered |
Product Type, Application, Material, End user |
| Key Companies Profiled |
TDK Corporation; Delta Electronics, Inc.; TE Connectivity; Littelfuse, Inc., and others |
| Regional Scope |
|
Major Challenges of the Cardiac Rhythm Management Devices Market
1. Regulatory Challenges and Approval Delays: The regulatory approval process for medical devices takes a significant amount of time. The FDA premarket approval process takes up to 18 months, while the EU Medical Device Regulation adds six months or more to this timeline. An example of regulatory bottlenecks includes the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan requesting extra clinical data, causing Boston Scientific to experience an eight-month delay in 2023 for its next-gen ICD approval. Furthermore, different companies can bypass long waits, like Medtronic demonstrated with its Aurora EV-ICD through real-world EU data to accelerate FDA approval and reveal how innovative methods can expedite regulatory procedures.
2. Price Controls and Reimbursement Barriers: Medical device pricing remains under international governmental surveillance as authorities monitor the market closely. Germany’s G-BA requires CRM devices to undergo a 20% price decrease, complicating pricing negotiations. An example of companies negotiating includes Abbott meeting France’s reimbursement challenge in 2023 by working out a risk-sharing deal with HAS, which is the French health authority. The agreement linked reimbursement amounts to patient outcomes and boosted access by 15%. Furthermore, around 40% of Medicaid patients receive ICDs in the U.S. because of the complex authorization requirements, while Boston Scientific’s “pay-for-performance” contracts demonstrate how value-based pricing models establish payment structures that match costs to actual benefits.
Opportunities and Trends in the Cardiac Rhythm Management Devices Market
1. Historical Patient Growth (2010–2020)
|
Country |
Patients (2010) |
Patients (2020) |
Growth (%) |
Key Driver |
|---|---|---|---|---|
|
USA |
2.1M |
3.8M |
81% |
Rising AFib cases, Medicare coverage |
|
Germany |
850K |
1.5M |
76% |
Aging population, universal healthcare |
|
France |
720K |
1.3M |
80% |
Reimbursement policies, telemedicine adoption |
|
Spain |
450K |
820K |
82% |
Increased CVD awareness |
|
Australia |
380K |
680K |
79% |
Government subsidies (PBS) |
|
Japan |
1.2M |
2.3M |
92% |
Super-aged society, NHI coverage |
|
India |
1.1M |
2.8M |
155% |
Urbanization, rising CVD cases |
|
China |
2.5M |
6.4M |
156% |
Healthcare reforms, middle-class expansion |
2. Revenue Opportunities for Manufacturers
A. Expanding in High-Growth Markets (India & China)
- Opportunity: India’s CRM market is projected to grow due to the rising CVD cases (330M by 2037).
- Example: Abbott’s local manufacturing in India reduced costs by 30%, capturing 18% market share.
- Revenue Potential: $1.2B by 2037 in India alone.
B. Remote Monitoring & AI-Driven CRM Devices
- Opportunity: 10.2% CAGR (2025–2037) in remote cardiac monitoring.
- Example: Medtronic’s LinQ II saw $450M revenue in 2023 due to AI analytics.
- Revenue Potential: $7.5 B global market by 2037.
C. Leadless Pacemakers (Next-Gen Tech)
- Opportunity: 9.3% CAGR (2025–2037), especially in Japan (40% adoption by 2037).
- Example: Boston Scientific’s Micra AV generated $1.1B in 2023.
- Revenue Potential: $5.5B by 2037.
3. Feasibility Models for Market Expansion
|
Strategy |
Example |
Outcome |
Market Applicability |
|---|---|---|---|
|
Local Manufacturing |
Abbott’s Chennai plant (India) |
30% cost reduction, 18% market share |
India, China, Brazil |
|
Public-Private Partnerships |
LivaNova & Apollo Hospitals (India) |
20% adoption boost |
Emerging markets |
|
Value-Based Pricing |
Medtronic’s 5-year ICD warranty (USA) |
25% fewer payer denials |
USA, Germany, Japan |
|
Leasing Models |
Biotronik’s "Pay-As-You-Go" pacemakers (Brazil) |
15% revenue growth |
Latin America, SE Asia |
4. Leading Companies & Their Strategies
|
Company |
Key Strategy |
Example |
Revenue Impact |
|---|---|---|---|
|
Medtronic |
AI-driven remote monitoring |
LinQ II with Google Cloud AI |
$450M (2023) |
|
Abbott |
Localized manufacturing in India |
Chennai plant cost optimization |
18% market share |
|
Boston Scientific |
Leadless pacemakers (Micra AV) |
FDA fast-track approval (2023) |
$1.1B (2023) |
|
Biotronik |
Affordability focus (emerging markets) |
25% price cut in India |
12% growth |
|
LivaNova |
Hospital partnerships |
Apollo Hospitals deal (India) |
20% adoption boost |
Cardiac Rhythm Management Devices Market: Regional Analysis
North America Cardiac Rhythm Management Devices Market Analysis
1. USA
|
Category |
Key Data |
|
Federal Budget Allocation |
9% of USA healthcare budget ($5B, 2023) |
|
Medicaid Support |
$1.2B allocated (2024); 10% more patients covered |
|
Medicare Funding |
15% rise (2020–2024), reaching $800M |
2. Canada
|
Category |
Key Data |
|
Federal Budget Allocation |
8% ($3.2 billion, 2023); 12% growth since 2020 |
|
Provincial Healthcare Spending |
18% increase (2021–2024); 200,000 patients served annually |
3. Mexico
|
Category |
Key Data |
|
Federal Healthcare Spending |
6.5% of budget (MXN 15B, 2023); 10% growth since 2021 |
|
Public and Private Sector Support |
20% private investment growth (2020–2024); 500+ new firms entered |
Comparative Analysis of North America CRM Devices Market
|
Category |
USA |
Canada |
Mexico |
|
Federal Budget Allocation |
9% ($5B, 2023) |
8% ($3.2B, 2023) |
6.5% (MXN 15B, 2023) |
|
Growth in Budget Allocation |
From 7.5% (2021) |
12% increase since 2020 |
10% increase since 2021 |
|
Medicaid/Provincial Support |
$1.2B (2024), +10% patients covered |
18% rise (2021–2024); 200K+ patients |
20% growth (2020–2024) |
Europe Cardiac Rhythm Management Devices Market Analysis
United Kingdom (Market Demand & Budget Allocation): Advancements in device technologies, alongside the growing number of cardiovascular disease cases, drive the UK Cardiac Rhythm Management Devices Market. The UK's healthcare budget allocation for CRM treatments reached 8% in 2023 after growing from 6.5% in 2020. Additionally, the aging population combined with the growing use of remote monitoring systems drives the increased demand for CRM devices.
Germany (Market Size & Government Spending): Germany stands as one of Europe’s top markets for CRM devices and expects to generate €1.5 billion in revenue by 2037 while maintaining a 5.2% CAGR between 2025 and 2037. Germany set aside around €4 billion for CRM treatments in 2024, representing a 12% increase in demand since 2021. Moreover, government initiatives to improve healthcare infrastructure and reimbursement policies have played a crucial role in driving market expansion.
France (Budget Allocation & Growth Trends): Experts forecast that France's CRM devices market will attain €1.04 billion by 2037 while growing at a compound annual growth rate of 5.3% between 2025 and 2037. Government initiatives fuel market growth through increased use of defibrillators and other sophisticated CRM devices.
European Union (Government Support): The European Union promotes the CRM devices market through the European Health Data Space initiative, supporting research and innovation efforts. Additionally, the European Union dedicated €2.5 billion in 2023 to stimulate CRM device development and adoption throughout its member states.
Asia Pacific Cardiac Rhythm Management Devices Market Analysis
Japan (Market Demand & Spending)
Japan dedicated around 12% of its healthcare budget to CRM treatments in 2024, highlighting a $3 billion growth since 2022. Additionally, CRM devices experience increased demand in Japan because 31% of its population is aging.
China (Market Data & Patient Analysis)
The government spent 15% more on CRM devices in the past five years while diagnosing over 1.5 million patients in 2023. Additionally, the “Healthy China 2030” initiative has given top priority to cardiovascular health, leading to increased demand for CRM devices.
India (Government Spending & Patient Numbers)
Government spending on CRM devices expanded by 18% from 2015 to 2023 to reach $1.8 billion annually while treating 2.4 million patients in 2023. Cardiovascular disease prevalence and technological progress function as main growth catalysts.
Malaysia (Government Spending & Patient Numbers)
CRM treatment requirements doubled for patients between 2013 and 2023, demonstrating increased demand for advanced cardiac care.
South Korea (Government Spending & Patient Numbers)
CRM device funding from the government has shown continuous growth, and substantial investments have been directed toward minimally invasive technologies. Additionally, CRM devices experience increased demand due to cardiovascular diseases being a primary reason for death worldwide.
Major Players of the Cardiac Rhythm Management Devices Market
Below are the areas covered for each company under the top 20 global manufacturers:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Here’s a list of the top 20 global manufacturers in the CRM Devices market:
Top 20 Global CRM Device Manufacturers (2024)
|
Rank |
Company Name |
Country |
Market Share |
|---|---|---|---|
|
1 |
Medtronic |
USA |
25% |
|
2 |
Abbott Laboratories |
USA |
20% |
|
3 |
Boston Scientific |
USA |
18% |
|
4 |
Biotronik |
Germany |
10% |
|
5 |
LivaNova |
UK |
6% |
|
6 |
MicroPort Scientific |
China |
5% |
|
7 |
Sorin Group (Now LivaNova) |
Italy |
4% |
|
8 |
Japan Lifeline |
Japan |
3.5% |
|
9 |
Lepu Medical |
China |
3% |
|
10 |
OSYPKA Medical |
Germany |
2.5% |
|
11 |
Shree Pacetronix |
India |
2% |
|
12 |
Cardiac Science |
USA |
1.8% |
|
13 |
BPL Medical Technologies |
India |
1.5% |
|
14 |
Nihon Kohden |
Japan |
1.5% |
|
15 |
SJM Medical (Now Abbott) |
USA |
1.2% |
|
16 |
Baxter International |
USA |
1% |
|
17 |
Integer Holdings |
USA |
0.8% |
|
18 |
Fukuda Denshi |
Japan |
0.7% |
|
19 |
Biosense Webster (J&J) |
USA |
0.6% |
|
20 |
Mediana |
South Korea |
0.5% |
Recent Market Development
Key Commercial Launches:
- Abbott's Assert-IQ Insertable Cardiac Monitor (ICM):
- Date: March 2024
- Details: Abbott received CE mark approval in Europe for its Assert-IQ ICM, designed for long-term remote monitoring of patients' heart rhythms for up to six years. This device enables healthcare providers to effectively manage patients experiencing irregular heartbeats, including challenging cases such as atrial fibrillation (AF).
- MicroPort CRM's ULYS ICD and INVICTA Defibrillation Lead:
- Date: October 2023
- Details: MicroPort CRM launched the ULYS Implantable Cardioverter Defibrillator (ICD) and INVICTA defibrillation lead in Japan. These products highlight MicroPort's commitment to advancing cardiac care technology and expanding its product offerings in the global market.
Technological Advancements:
- Medtronic's Leadless Pacemaker with Remote Monitoring:
- Date: September 2024
- Details: Medtronic introduced a leadless pacemaker equipped with remote monitoring capabilities, enabling continuous heart rhythm tracking for enhanced patient safety. This advancement allows for timely interventions and personalized patient care.
- Johnson & Johnson's Varipulse Heart Device:
- Date: February 2025
- Details: Johnson & Johnson resumed the limited market release of its Varipulse heart device in the United States after confirming through an investigation that the devices function as intended. Varipulse uses a pulsed field ablation technique to treat certain abnormal heart rhythm conditions.
Cardiac Rhythm Management Devices Market : Segmentation
The cardiac rhythm management devices market research report provides comprehensive industry analysis with revenue estimates and forecasts (USD billion) from 2025 to 2037 across the following segments:
Market Size, By Product Type:
- Implantable Cardioverter-Defibrillators (ICDs)
- Leadless Pacemakers (Disruptive Innovation)
- Remote Cardiac Monitoring
Market Size, By Application:
- Arrhythmia Management
- Heart Failure Treatment
- Post-Surgical Cardiac Care
Market Size, By Technology:
- Wireless Transmission Systems
- AI-Integrated Monitoring Solutions
- Battery Optimization Technologies
Market Size, By End user:
- Hospitals and Clinics
- Specialty Cardiac Centers
- Home Care Settings
- Academic & Research Institutes
Why Choose Kenneth Research ?
-
Insight with Impact : We don’t just gather data — we uncover stories, trends, and opportunities that fuel business growth.
-
Experts Who Get It : Our team speaks your industry’s language and knows what really matters to your customers and market.
-
Custom-Built for You : Forget one-size-fits-all. We craft research and consulting solutions as unique as your business vision.
-
Partners, Not Just Providers : We work with you, not for you — collaborating closely to turn insights into smart, strategic moves.
-
Results That Speak : Our work powers brands, startups, and industry leaders alike — with a track record of ideas that work in the real world.
Report ID: 10352557 |
Published Date: 28 Apr 2025 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
